Eris Biotech GTM brain

category

market profile

• text: Tumor immune evasion undermines cancer treatment; Eris is developing an inhibitor intended to restore immune surveillance.
• text: Its first intended indication is mesothelioma, with a broader solid tumor portfolio described by the founders.
• text: The company is developing a drug, rather than marketing an approved product; efficacy and safety need independent clinical substantiation.

personas

• title: Oncology pharmaceutical licensing and business development leader
  pains:

  • Finding differentiated immuno-oncology assets with tractable development and licensing rights
  • Assessing preclinical evidence, target biology and the path to clinical trials
• title: Thoracic oncology clinical research leader
  pains:

  • Limited options and poor outcomes for patients with mesothelioma
  • Identifying eligible patients and testing whether a new approach offers clinically meaningful benefit
• title: Translational immuno-oncology scientist
  pains:

  • Tumor-derived immune suppression can prevent effective immune surveillance
  • Needs mechanistic and biomarker evidence to assess which patients could respond

icp

• text: Potential partners include pharmaceutical and biotech companies with solid tumor immunotherapy portfolios and external licensing teams; this is an inferred partner profile.
• text: Potential research sites include oncology centers with thoracic oncology and mesothelioma trial capabilities; commercial buyers and deal terms are not disclosed.

message pillars

• text: Center the mission on mobilizing immunity against cancer.
• text: Describe the approach as small molecules that reactivate antitumor immunity.
• text: Emphasize a pathway aimed at blocking immune evasion.

objections

• objection: What evidence supports efficacy and patient safety?
  response: Request preclinical data, trial status and study designs. The company's safety claim is not proof of clinical safety.
• objection: How does this differ from other immunotherapies for mesothelioma?
  response: Review the proposed vesicle mechanism, patient selection and comparative data with the team; outcomes are not established here.
• objection: Can the drug reach patients at scale?
  response: The oral route is part of the design, but manufacturing, approval and access plans require confirmation.

competitors

• name: Incyte
  website: https://www.incyte.com/
  why: Develops oncology small molecules and is identified as a possible competitor in a company profile.
• name: Bristol Myers Squibb
  why: Competes in cancer immunotherapy and the mesothelioma treatment landscape, although its modality differs.

influencers

• name: Evita Weagel
  url: https://intch.org/18714291
  why: Eris co-founder and CEO discusses its immunotherapy and partnerships.

keywords

• mesothelioma immunotherapy
• tumor immune evasion
• small molecule immuno oncology
• tumor exosome inhibitor
• solid tumor therapeutic partnerships
• oral cancer immunotherapy

voice

• Mission-led
• Accessible scientific language
• Confident about its therapeutic hypothesis

signals

• text: An oncology drug company announces a search for externally developed immunotherapy assets or collaborations.
• text: A cancer center expands mesothelioma trials or translational immune-oncology research.

pricing

motion

channels

• LinkedIn

confidence

Founders

• name: Evita Weagel
  title: Founder/CEO
  role: CEO
  bio: PhD in microbiology and molecular biology with an emphasis in cancer immunology, working on developing drugs that reawaken the immune system to fight cancer. First-generation immigrant from Peru. Mom of two boys.
• name: Rachel Garlick
  title: Founder
  role: Founder
  bio: PhD in Immunology from Dartmouth College. Engineered many novel cancer immunotherapies. We build cancer drugs that reawaken the immune system to fight cancer for you. No tox, no side effects, and most importantly -- no cancer.